Michael Martin — Co-Founder and Chief Operating Officer at Aurinia Pharmaceuticals

Mr. Michael R. Martin is Co-Founder of Aurinia Pharmaceuticals Inc. and has been its Chief Operating Officer since September 2013. Mr. Martin served as the Chief Business Officer at Aurinia Pharmaceuticals Inc. since September 23, 2013. He is responsible for managing company functions such as corporate and business development, alliance management, marketing, finance and internal company operations. Mr. Martin is a biotech/pharmaceutical executive with over 18 years indusmix of strategic planning, marketing, commercial operations, business development, licensing and people management skills. Mr. Martin joined Aurinia from Vifor Pharma where he held the position of Director of Global Business Development & Licensing. He served as the President at Aurinia Pharmaceuticals Inc. Prior to Vifor, Mr. Martin was a key member of the business development team that saw Aspreva sold to Galenica for $915M. Upon joining Aspreva in 2004, Mr. Martin initiated the strategic launch planning process for CellCept??? in ???less-common??? autoimmune diseases. These included such indications as Pemphigus Vulgaris, Myasthenia Gravis and Lupus Nephritis. Prior thereto, Mr. Martin held a variety of progressively senior commercial positions at Schering-Plough. Most recently, Mr. Martin has spent time in Europe where he was responsible for the Rheumatology business unit for Remicade??? in France. There, Mr. Martin had full profit and loss responsibilities and had direct responsibility for the sales team, the marketing team and the infusion access team. In addition while at Schering-Plough, Mr. Martin was the brand manager responsible for the Canadian launch of Remicade (infliximab), which ultimately became the most successful product launch in Canadian history. Mr. Martin started his career in the industry in the sales organization of Schering-Plough where he received multiple awards and recognition while rapidly progressing towards the prior mentioned roles. He had been a Director of Aurinia Pharmaceuticals Inc. since September 20, 2013. Mr. Martin has been a Director at Isotechnika Pharma Inc. since August 15, 2013.